Sanofi has signed up Boehringer Ingelheim as its partner to manufacture monoclonal antibodies.
Under the terms of the agreement, the French drugmaker will have access to Boehringer’s capabilities in Biberach, Germany to transfer and manufacture therapeutic mAbs. Initial product transfers will begin in early 2015.
Sanofi says that the rationale behind the deal, the financial terms for which were not disclosed, is to reinforce its manufacturing capacity “to support upcoming product launches”. Some 72% of its R&D projects are in biologics, nearly half of which are mAbs.
Wolfram Carius, head of biologics at Sanofi, said Boehringer is “a highly capable and experienced partner to complement our continued alliance with Regeneron and the investments we are making in building our own internal capabilities”.
